José Lopes, PhD, managing science editor —

CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission for the treatment of multiple myeloma, the company announced. The status follows the fast track designation granted in May by the U.S. Food and Drug…

Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with dexamethasone could be effective if the patients respond partially after the first treatment cycle, according to new research. The study, “Response to…

Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing complete cancer disappearance, according to top-line results of a Phase 2 clinical trial. The open-label GRIFFIN study (NCT02874742) includes 223 patients eligible for high-dose…

Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed or refractory multiple myeloma, according to updated results of a Phase 2 study. The study, “Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory…

The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with relapsed or refractory multiple myeloma who received the most effective dose in a Phase 1 clinical trial. The study, “Evaluation of AMG 420, an anti-BCMA bispecific…

An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable safety in adults with relapsed or refractory multiple myeloma, according to a Phase 3 trial. Trial results were presented in a study, “…

The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma patients not eligible for a stem cell transplant or thalidomide therapy. “This decision is fantastic news for the myeloma patients who will be able…

New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year free of disease progression in patients with relapsed or refractory multiple myeloma. The results — covering 14 additional months of follow-up — again show 60% of these advanced patients responding…

OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the Institute for Myeloma and Bone Cancer Research. The first patent family includes the patent “Diagnostic, prognostic, and monitoring methods for multiple…

The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone for patients with multiple myeloma who failed at least three prior therapies. This means that the FDA will decide whether to approve the oral…